- In June 2024, AbbVie Inc. has developed and marketed IL inhibitors, including Skyrizi (risankizumab), targeting IL-23 for autoimmune conditions such as psoriasis and Crohn’s disease. The company has emphasized innovation through rigorous research and development to improve patient outcomes and address unmet medical needs in chronic inflammatory diseases.
- In June 2020, Eli Lilly and Company has established a reputation for products such as Taltz (ixekizumab) and Mirikizumab, targeting IL-17 and IL-23, respectively. The company is focused on advancing therapeutic options for autoimmune diseases through strategic partnerships and clinical trials to improve treatment efficacy and safety profiles.
